RxDoctor Payments Data

Mohammad Khan, MD

Hematology & Oncology · Louisville, KYNPI 1790710481

Payments from drug & device makers

$11,351in general payments, 2019–2025

Across 625 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Pfizer$933
  • Merck$661
  • E.r. Squibb & Sons, L.L.C.$660
  • Daiichi Sankyo Inc.$578
  • Bristol Myers Squibb$514
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$11,08898%
  • Education$2622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis66$1,137
Pfizer62$933
Merck38$661
E.r. Squibb & Sons, L.L.C.45$660
Daiichi Sankyo Inc.25$578
Bristol Myers Squibb27$514
Johnson & Johnson(2 entities)39$483
Sanofi19$397
Amgen23$382
Seagen Inc.19$373
AstraZeneca16$363
Eisai Inc.19$358
Regeneron Healthcare Solutions, Inc.12$280
Beigene USA, Inc.14$245
GSK12$241
Genentech USA, Inc.15$236
Gilead(2 entities)13$229
Pharmacyclics LLC, An Abbvie Company8$208
Rigel Pharmaceuticals, Inc.10$179
Ipsen Biopharmaceuticals, Inc6$170
Incyte Corporation11$169
Puma Biotechnology, Inc.10$168
Boehringer Ingelheim8$168
Lilly USA, LLC10$166
Adaptive Biotechnologies Corporation2$164
AbbVie7$147
Foundation Medicine, Inc.4$147
AVEO Pharmaceuticals, Inc.9$134
Astellas Pharma US Inc6$106
Cumberland Pharmaceuticals, Inc.1$99
ADC Therapeutics America, Inc.4$68
Takeda Pharmaceuticals U.S.A., Inc.4$67
Mirati Therapeutics, Inc.4$65
Actelion Pharmaceuticals US, Inc.3$64
Kyowa Kirin, Inc.4$63
Sumitomo Pharma America, Inc.3$62
Blueprint Medicines Corporation3$58
Terumo Medical Corporation1$53
Array Biopharma Inc4$53
Pharmacosmos Therapeutics Inc.3$52
Tempus AI, Inc2$50
Sobi, Inc2$50
Beone Medicines USA, Inc.2$48
Bayer3$41
Agios Pharmaceuticals, Inc.2$38
Jazz Pharmaceuticals Inc.2$35
Alnylam Pharmaceuticals Inc.2$34
Clovis Oncology, Inc.2$33
Immunocore Limited2$30
Fennec Pharmaceuticals, Inc.2$28
Mayne Pharma Commercial LLC1$27
G1 Therapeutics, Inc.2$26
Abbott1$22
Accord Healthcare, Inc.1$22
Coherus Oncology, Inc.1$22
Stemline Therapeutics Inc.1$22
TG Therapeutics, Inc.1$20
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$17
Tersera Therapeutics LLC1$16
Octapharma USA, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,351 in reported general payments places this provider in the 50th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$118,206
Medicare patients
316
Services billed
1,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib127$2,015,111
BrukinsaZanubrutinib33$469,356
PomalystPomalidomide13$289,202
Lenalidomide20$209,607
VenclextaVenetoclax14$193,332
CalquenceAcalabrutinib Maleate12$179,166
EliquisApixaban176$157,900
Imatinib Mesylate23$42,240
XareltoRivaroxaban30$38,035
Enoxaparin Sodium44$18,896
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen121$4,663
Ondansetron OdtOndansetron52$2,002
Anastrozole113$1,957
SpsSodium Polystyrene Sulfon/Sorb18$1,286
Oxycodone Hcl40$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$208$2,015,111127 claims
Beigene USA, Inc.Brukinsa$245$469,35633 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$660$289,20213 claims
AbbVieVenclexta$147$193,33214 claims
AstraZenecaCalquence$363$179,16612 claims
PfizerEliquis$933$157,900176 claims
Johnson & JohnsonXarelto$483$38,03530 claims
Lilly USA, LLCOlanzapine$166$90035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →